A
Aaron Lisberg
Researcher at University of Minnesota
Publications - 22
Citations - 5586
Aaron Lisberg is an academic researcher from University of Minnesota. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 5418 citations.
Papers
More filters
Journal ArticleDOI
Pluripotency of mesenchymal stem cells derived from adult marrow
Yuehua Jiang,Balkrishna N. Jahagirdar,R. Lee Reinhardt,Robert E. Schwartz,C. Dirk Keene,Xilma R. Ortiz-Gonzalez,Morayma Reyes,Todd Lenvik,Troy C. Lund,Mark Blackstad,Jingbo Du,Sara Aldrich,Aaron Lisberg,Walter C. Low,David A. Largaespada,Catherine M. Verfaillie +15 more
TL;DR: It is reported here that cells co-purifying with mesenchymal stem cells—termed here multipotent adult progenitor cells or MAPCs—differentiate, at the single cell level, not only into meschymal cells, but also cells with visceral mesoderm, neuroectoderm and endoderm characteristics in vitro.
Journal ArticleDOI
Erratum: Pluripotency of mesenchymal stem cells derived from adult marrow (Nature (2002) 418 (41-49) DOI: 10.1038/nature00870)
Yuehua Jiang,Balkrishna N. Jahagirdar,R. Lee Reinhardt,Robert E. Schwartz,C. Dirk Keene,Xilma R. Ortiz-Gonzalez,Morayma Reyes,Todd Lenvik,Troy C. Lund,Mark Blackstad,Jingbo Du,Sara Aldrich,Aaron Lisberg,Walter C. Low,David A. Largaespada,Catherine M. Verfaillie +15 more
TL;DR: Questions raised recently about flow cytometry data reported in Fig. 1 and the experimental approach used to generate them reviewed by flow cytometer experts are addressed.
Journal ArticleDOI
Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
Ian E. Krop,Dejan Juric,T. Shimizu,Anthony W. Tolcher,Alexander I. Spira,Toru Mukohara,Aaron Lisberg,Takahiro Kogawa,Kyriakos P. Papadopoulos,Erika Hamilton,Senthilkumar Damodaran,Jonathan Greenberg,Wen Gu,Fumiaki Kobayashi,F. Guevara,Takahiro Jikoh,Yui Kawasaki,Funda Meric-Bernstam,Aditya Bardia +18 more
TL;DR: Preliminary results from the phase 1 TROPION-PanTumor01 study demonstrate that Dato-DXd has encouraging antitumor activity and a manageable safety profile in patients with non-small cell lung cancer (NSCLC) and those with triple-negative breast cancer (TNBC) and with patients with advanced/metastatic TNBC who relapsed/progressed on standard therapies.
Journal ArticleDOI
Spatial mapping of mitochondrial networks and bioenergetics in lung cancer
Ming Han,Eric A. Bushong,Mayuko Segawa,Alexandre Tiard,A. Wong,Morgan R Brady,Milica Momcilovic,Dane M. Wolf,Ralph Zhang,Anton Petcherski,Matthew Madany,Shili Xu,Jason T. Lee,Masha V. Poyurovsky,Kellen L. Olszewski,Travis Holloway,Adrian Gomez,Maie A. St. John,Steven M. Dubinett,Carla M. Koehler,Orian S. Shirihai,Linsey Stiles,Aaron Lisberg,S. Soatto,Saman Sadeghi,Mark H. Ellisman,David B. Shackelford +26 more
TL;DR: In this paper , structural and functional analysis of mitochondria networks and bioenergetic phenotypes in non-small cell lung cancer (NSCLC) using an integrated platform consisting of positron emission tomography imaging, respirometry and three-dimensional scanning block-face electron microscopy.
Journal ArticleDOI
Abstract P6-10-03: Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
Aditya Bardia,Ian E. Krop,Funda Meric-Bernstam,Anthony W. Tolcher,Toru Mukohara,Aaron Lisberg,T. Shimizu,Erika Hamilton,Alexander I. Spira,Kyriakos P. Papadopoulos,Jonathan Greenberg,Wen Gu,Fumiaki Kobayashi,Hong Zebger-Gong,Yui Kawasaki,Rie Wong,Takahiro Kogawa +16 more
TL;DR: The TROPION-PanTumor01 (NCT03401385) study as discussed by the authors evaluated Dato-DXd 6 mg/kg IV Q3W in patients with advanced/metastatic TNBC.